28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too
Executive Summary
Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.
You may also be interested in...
Aveo's Tivozanib Under CHMP Spotlight If Negative OS Trend Continues In TIVO-3
An August 2019 analysis of overall survival in the TIVO-3 study of Aveo’s tivozanib in advanced renal cell carcinoma is now an interim rather than a final analysis, but EU regulators may take action if a negative overall survival trend is found to be continuing.
Dupixent Stopped at UK Gate For AD As EMA Agrees To Review It In Asthma
Dupixent has been initially rejected by NICE to treat eczema on cost grounds, but Sanofi remains hopeful of UK entry - and the biologic's overall promise.
EU Orphan Designations Fall Sharply In 2017
The number of medicines awarded orphan designation in the EU has fallen for the first time since 2013. In 2017 there were 144, considerably fewer than in 2016 when there were 209. In the meantime, orphan drug advocacy group Eurordis says radical change is needed if patients are to have broader access to these important but often highly priced drugs.